Emadian Saravi Omid, Naghshvar Farshad, Torabizadeh Zhila, Sheidaei Somayeh
Department of Pathology, Faculty of Medicine, Mazandaran University of Medical Science, Sari, Iran.
Department of Pathology, Gastrointestinal Cancer Research Center, Mazandaran University of Medical Science, Sari, Iran.
Iran Biomed J. 2019 May;23(3):184-9. doi: 10.29252/.23.3.184. Epub 2018 Sep 17.
Cancer stem cells (CSCs) are a group of tumor cells with self-renewal property and differentiation potential. CSCs play a crucial role in malignant progression of several types of tumors. However, what is still controversial is the clinicopathological relationship between the Nanog marker and its prognostic value in the patients with breast cancer. The expression of Nanog in the patients with breast cancer and its correlation with clinicopathological prognostic factors was explored in the present study.
A sample of 120 breast cancer tissues was obtained from the patients who referred to Imam Khomeini Hospital in Sari City, Iran during January 2012 and December 2016. The associations between Nanog expression and clinicopathological factors were analyzed based on immunohistochemical analysis.
The expression of Nanog was detected in 67 (55.8%) patients with a high expression rate in 24 (36%) cases (staining index ≥3). Moreover, there was a statistically significant relationship between Nanog expression and clinicopathological factors, including tumor grade (p = 0.001), lymph node metastasis (p = 0.01), and the stage of the disease (p = 0.003).
Findings of the study indicate that Nanog may act as a biomarker for prognostic prediction in patients with breast cancer.
癌症干细胞（CSCs）是一组具有自我更新特性和分化潜能的肿瘤细胞。癌症干细胞在多种肿瘤的恶性进展中起着关键作用。然而，Nanog标志物与乳腺癌患者的临床病理关系及其预后价值仍存在争议。本研究探讨了Nanog在乳腺癌患者中的表达及其与临床病理预后因素的相关性。
2012年1月至2016年12月期间，从伊朗萨里市伊玛目霍梅尼医院就诊的患者中获取了120份乳腺癌组织样本。基于免疫组织化学分析，分析了Nanog表达与临床病理因素之间的关联。
在67例（55.8%）患者中检测到Nanog表达，其中24例（36%）高表达（染色指数≥3）。此外，Nanog表达与临床病理因素之间存在统计学显著关系，包括肿瘤分级（p = 0.001）、淋巴结转移（p = 0.01）和疾病分期（p = 0.003）。
该研究结果表明，Nanog可能作为乳腺癌患者预后预测的生物标志物。
